Paliperidone ER + Paliperidone ER + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizoaffective Disorder
Conditions
Schizoaffective Disorder, Psychotic Disorder
Trial Timeline
Nov 1, 2006 → Feb 1, 2008
NCT ID
NCT00397033About Paliperidone ER + Paliperidone ER + Placebo
Paliperidone ER + Paliperidone ER + Placebo is a phase 3 stage product being developed by Johnson & Johnson for Schizoaffective Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00397033. Target conditions include Schizoaffective Disorder, Psychotic Disorder.
What happened to similar drugs?
2 of 4 similar drugs in Schizoaffective Disorder were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00397033 | Phase 3 | Completed |
Competing Products
9 competing products in Schizoaffective Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Haloperidol + Olanzapine | Eli Lilly | Approved | 43 |
| Lurasidone HCl | Sumitomo Pharma | Phase 1 | 29 |
| Placebo + Paliperidone ER + Paliperidone ER | Johnson & Johnson | Phase 3 | 40 |
| RO6889450 + Placebo + Risperidone | Roche | Phase 2 | 35 |
| RO6889450 + Placebo | Roche | Phase 2 | 27 |
| AMG 581 + Placebo + Midazolam | Amgen | Phase 1 | 29 |
| AMG 581 + Placebo | Amgen | Phase 1 | 29 |
| Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone + Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone | Pfizer | Phase 3 | 40 |
| Ziprasidone | Pfizer | Approved | 43 |